Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Using a design flow put together by Mentor Graphics and Altera, designers can implement complex DSP algorithms in high-performance FPGAs directly from ANSI C++ code. The flow, which is based on Altera ...

A major development has emerged from Arwal in Bihar, where a local court has issued a non-bailable warrant against DSP Kriti Kamal and multiple police personnel in a high-profile police brutality case ...